Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Shizhen Wang

    TitleAssociate Professor In Residence
    SchoolUniversity of California, San Diego
    DepartmentPathology
    Address9500 Gilman Drive #0612
    CA La Jolla 92093
    Phone858-246-2464
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Targeting Chemotherapy-induced Breast Cancer Stemness
      NIH/NCI R01CA206911Aug 1, 2017 - Jul 31, 2022
      Role: Principal Investigator
      Role of breast cancer-secreted miRNA in directing a stromal metabolic plasticity
      NIH/NCI R01CA218140Aug 1, 2017 - Jul 31, 2022
      Role: Principal Investigator
      Role of miR-105 in breast cancer metastasis
      NIH/NCI R01CA166020Sep 1, 2012 - Jun 30, 2017
      Role: Principal Investigator
      Mechanism of chemoresistance mediated by TGF-beta
      NIH/NCI R01CA163586May 1, 2012 - Mar 31, 2017
      Role: Principal Investigator
      Crosstalk TGFbeta and HER2 (ErbB2) Signaling in Mammary Tumorigenesis
      NIH/NCI R00CA125892Jul 25, 2007 - Jun 30, 2012
      Role: Principal Investigator
      Crosstalk TGFbeta and HER2 (ErbB2) Signaling in Mammary Tumorigenesis
      NIH/NCI K99CA125892Jul 25, 2007 - Jun 30, 2009
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Liu L, Zhang L, Yang L, Li H, Li R, Yu J, Yang L, Wei F, Yan C, Sun Q, Zhao H, Yang F, Jin H, Wang J, Wang S, Ren X. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. Front Immunol. 2017; 8:404. PMID: 28484448.
        View in: PubMed
      2. Chin AR, Wang S. Cancer-derived extracellular vesicles: the 'soil conditioner' in breast cancer metastasis? Cancer Metastasis Rev. 2016 Dec; 35(4):669-676. PMID: 27838868.
        View in: PubMed
      3. Zhang K, Wu X, Wang J, Lopez J, Zhou W, Yang L, Wang S, Raz DJ, Kim JY. Circulating miRNA profile in esophageal adenocarcinoma. Am J Cancer Res. 2016; 6(11):2713-2721. PMID: 27904783.
        View in: PubMed
      4. Chin AR, Wang S. Cancer Tills the Premetastatic Field: Mechanistic Basis and Clinical Implications. Clin Cancer Res. 2016 Aug 01; 22(15):3725-33. PMID: 27252414; PMCID: PMC4970897 [Available on 08/01/17].
      5. Chin AR, Fong MY, Somlo G, Wu J, Swiderski P, Wu X, Wang S. Cross-kingdom inhibition of breast cancer growth by plant miR159. Cell Res. 2016 Feb; 26(2):217-28. PMID: 26794868; PMCID: PMC4746606 [Available on 02/01/17].
      6. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O'Connor ST, Li S, Chin AR, Somlo G, Palomares M, Li Z, Tremblay JR, Tsuyada A, Sun G, Reid MA, Wu X, Swiderski P, Ren X, Shi Y, Kong M, Zhong W, Chen Y, Wang S. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015 Feb; 17(2):183-94. PMID: 25621950; PMCID: PMC4380143.
      7. Fong MY, Wang S. The exploits of cancer's greedy sweet-tooth. Cell Cycle. 2015; 14(12):1768-9. PMID: 25928026; PMCID: PMC4615071.
      8. Ashby J, Flack K, Jimenez LA, Duan Y, Khatib AK, Somlo G, Wang S, Cui X, Zhong W. Distribution profiling of circulating microRNAs in serum. Anal Chem. 2014 Sep 16; 86(18):9343-9. PMID: 25191694.
        View in: PubMed
      9. Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang S. TGFß induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. Mol Cancer Res. 2014 Nov; 12(11):1597-609. PMID: 25103497; PMCID: PMC4233161.
      10. Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, Chin AR, Ren X, Gugiu BG, Meng Z, Huang W, Ngo V, Kortylewski M, Wang S. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-?B. Sci Rep. 2014 Jul 18; 4:5750. PMID: 25034888; PMCID: PMC4102923.
      11. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang S. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014 Apr 14; 25(4):501-15. PMID: 24735924; PMCID: PMC4016197.
      12. Chin AR, Wang S. Cytokines driving breast cancer stemness. Mol Cell Endocrinol. 2014 Jan 25; 382(1):598-602. PMID: 23562748.
        View in: PubMed
      13. Tsuyada A, Wang S. Fibroblast-derived CCL2 induces cancer stem cells--response. Cancer Res. 2013 Jan 15; 73(2):1032-3. PMID: 23316033; PMCID: PMC4132662.
      14. Wang S, Lin RJ. MicroRNA and HER2-overexpressing cancer. Microrna. 2013; 2(2):137-47. PMID: 25070783; PMCID: PMC4120065.
      15. Zheng YW, Li H, Yu JP, Zhao H, Wang S, Ren XB. Interferon-?s: special immunomodulatory agents and potential therapeutic targets. J Innate Immun. 2013; 5(3):209-18. PMID: 23207147.
        View in: PubMed
      16. Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang S, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov; 61(11):2125-33. PMID: 22581306.
        View in: PubMed
      17. Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, Chen S, Zhou W, Yu Y, Wang YZ, Ren X, Li H, Scherle P, Kuroki Y, Wang S. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012 Jun 01; 72(11):2768-79. PMID: 22472119; PMCID: PMC3367125.
      18. Chandra M, Zang S, Li H, Zimmerman LJ, Champer J, Tsuyada A, Chow A, Zhou W, Yu Y, Gao H, Ren X, Lin RJ, Wang S. Nuclear translocation of type I transforming growth factor ß receptor confers a novel function in RNA processing. Mol Cell Biol. 2012 Jun; 32(12):2183-95. PMID: 22473997; PMCID: PMC3372271.
      19. Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang S. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012 Mar 08; 10:42. PMID: 22400902; PMCID: PMC3342150.
      20. Zhang J, Li H, Yu JP, Wang S, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 2012 May 01; 130(9):1971-80. PMID: 22025331.
        View in: PubMed
      21. Yu J, Sun J, Wang S, Li H, Cao S, Cong Y, Liu J, Ren X. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. 2011; 2011:469135. PMID: 22110525; PMCID: PMC3202140.
      22. Chow A, Arteaga CL, Wang S. When tumor suppressor TGFß meets the HER2 (ERBB2) oncogene. J Mammary Gland Biol Neoplasia. 2011 Jun; 16(2):81-8. PMID: 21590373; PMCID: PMC3398103.
      23. Wang S. The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-ß Signaling in Breast Cancer Malignancy. J Signal Transduct. 2011; 2011:804236. PMID: 21637380; PMCID: PMC3101605.
      24. Ghosh R, Narasanna A, Wang S, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011 Mar 01; 71(5):1871-82. PMID: 21324925; PMCID: PMC3221734.
      25. Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang S. Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor ß contributes to chemoresistance in breast cancer cells. Mol Cancer Res. 2010 Dec; 8(12):1633-42. PMID: 21047769; PMCID: PMC3059495.
      26. Rejniak KA, Wang S, Bryce NS, Chang H, Parvin B, Jourquin J, Estrada L, Gray JW, Arteaga CL, Weaver AM, Quaranta V, Anderson AR. Linking changes in epithelial morphogenesis to cancer mutations using computational modeling. PLoS Comput Biol. 2010 Aug 26; 6(8). PMID: 20865159; PMCID: PMC2928778.
      27. Wang S, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. A mathematical model quantifies proliferation and motility effects of TGF-ß on cancer cells. Comput Math Methods Med. 2009 Mar; 10(1):71-83. PMID: 26000030.
        View in: PubMed
      28. Wang S, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 2009 Jan 15; 69(2):475-82. PMID: 19147560; PMCID: PMC2629389.
      29. Wang S, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol. 2008 Sep; 28(18):5605-20. PMID: 18625725; PMCID: PMC2546920.
      30. Guix M, Faber AC, Wang S, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008 Jul; 118(7):2609-19. PMID: 18568074; PMCID: PMC2430495.
      31. Qu S, Cai Q, Gao YT, Lu W, Cai H, Su Y, Wang S, Shu XO, Zheng W. ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study. Breast Cancer Res Treat. 2008 Jul; 110(1):169-76. PMID: 17687647.
        View in: PubMed
      32. Hinow P, Wang S, Arteaga CL, Webb GF. relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor Biol Med Model. 2007 Apr 03; 4:14. PMID: 17407594; PMCID: PMC1852549.
      33. Wang S, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem. 2007 Feb 23; 282(8):5661-9. PMID: 17204482; PMCID: PMC4015524.
      34. Friedman DB, Wang S, Whitwell CW, Caprioli RM, Arteaga CL. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. Mol Cell Proteomics. 2007 Jan; 6(1):150-69. PMID: 17028091.
        View in: PubMed
      35. Qu S, Rinehart C, Wu HH, Wang S, Carter B, Xin H, Kotlikoff M, Arteaga CL. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis. 2006 Oct; 44(10):477-86. PMID: 16991114.
        View in: PubMed
      36. Wang S, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 2006 Oct 01; 66(19):9591-600. PMID: 17018616.
        View in: PubMed
      37. Biswas S, Criswell TL, Wang S, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4142-6. PMID: 16857784.
        View in: PubMed
      38. Wang S, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006 Jul; 10(1):25-38. PMID: 16843263.
        View in: PubMed
      39. Wu FY, Wang S, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 2006 Feb 15; 66(4):2162-72. PMID: 16489017.
        View in: PubMed
      40. Wang S, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol Cell Biol. 2005 Jun; 25(11):4703-15. PMID: 15899872; PMCID: PMC1140650.
      41. Yu Y, Wang S, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005 Jan; 22(1):59-70. PMID: 15664159.
        View in: PubMed
      42. Wu FY, Wang S, Chen H, Wang L, Hayward SD, Hayward GS. CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J Virol. 2004 May; 78(9):4847-65. PMID: 15078966; PMCID: PMC387681.
      43. Wang S, Wu FY, Chen H, Shamay M, Zheng Q, Hayward GS. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J Virol. 2004 Apr; 78(8):4248-67. PMID: 15047839; PMCID: PMC374264.
      44. Wang S, Wu FY, Yu Y, Hayward GS. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol. 2003 Sep; 77(17):9590-612. PMID: 12915572; PMCID: PMC187379.
      45. Wu FY, Wang S, Tang QQ, Fujimuro M, Chiou CJ, Zheng Q, Chen H, Hayward SD, Lane MD, Hayward GS. Cell cycle arrest by Kaposi's sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p21(CIP-1). J Virol. 2003 Aug; 77(16):8893-914. PMID: 12885907; PMCID: PMC167214.
      46. Wu FY, Chen H, Wang S, ApRhys CM, Liao G, Fujimuro M, Farrell CJ, Huang J, Hayward SD, Hayward GS. CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle. J Virol. 2003 Jan; 77(2):1481-500. PMID: 12502863; PMCID: PMC140856.
      47. Wang S, Wu FY, Fujimuro M, Zong J, Hayward SD, Hayward GS. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J Virol. 2003 Jan; 77(1):600-23. PMID: 12477864; PMCID: PMC140597.